Patents by Inventor Steven R. Wiley

Steven R. Wiley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20020110853
    Abstract: The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.
    Type: Application
    Filed: June 18, 2001
    Publication date: August 15, 2002
    Inventor: Steven R. Wiley
  • Publication number: 20020041876
    Abstract: The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.
    Type: Application
    Filed: December 19, 2000
    Publication date: April 11, 2002
    Inventor: Steven R. Wiley
  • Patent number: 6284236
    Abstract: A novel cytokine designated TRAIL induces apoptosis of certain target cells, including cancer cells and virally infected cells. Isolated DNA sequences encoding TRAIL are disclosed, along with expression vectors and transformed host cells useful in producing TRAIL polypeptides. Antibodies that specifically bind TRAIL are provided as well.
    Type: Grant
    Filed: May 26, 1999
    Date of Patent: September 4, 2001
    Assignee: Immunex Corporation
    Inventors: Steven R. Wiley, Raymond G. Goodwin
  • Patent number: 6207642
    Abstract: An isolated clone consisting of sequences transcribed from the TREPA gene. Also provided are human polypeptides translated from said TREPA sequences and a procedure for producing such polypeptide by recombinant techniques. Also provided are a procedure for producing soluble biologically active TREPA, which may be used to treat deficiencies of TREPA and diseases conditions ameliorated by TREPA. Antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such polypeptide and therefore may be used therapeutically to treat TREPA-associated diseases, tumors or metastastases are disclosed. Also disclosed is the use of said antibodies, agonists and inhibitors as well as the nucleic acid sequences to screen for, diagnose, prognosticate, stage and monitor conditions and diseases attributable to TREPA, especially inflammation.
    Type: Grant
    Filed: June 26, 1998
    Date of Patent: March 27, 2001
    Assignee: Abbott Laboratories
    Inventor: Steven R. Wiley
  • Patent number: 6171787
    Abstract: An isolated clone consisting of sequences transcribed from the TNF-gamma gene. Also provided are human polypeptides translated from said TNF-gamma sequences and a procedure for producing such polypeptide by recombinant techniques. Also provided are a procedure for producing soluble biologically active TNF-gamma, which may be used to treat deficiencies of TNF-gamma and diseases conditions ameliorated by TNF-gamma. Antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such polypeptide and therefore may be used therapeutically to treat TNF-gamma associated diseases, tumors or metastastases are disclosed. Also disclosed is the use of said antibodies, agonists and inhibitors as well as the nucleic acid sequences to screen for, diagnose, prognosticate, stage and monitor conditions and diseases attributable to TNF-gamma, especially inflammation.
    Type: Grant
    Filed: June 26, 1997
    Date of Patent: January 9, 2001
    Assignee: Abbott Laboratories
    Inventor: Steven R. Wiley
  • Patent number: 5763223
    Abstract: A novel cytokine designated TRAIL induces apoptosis of certain target cells, including cancer cells and virally infected cells. Isolated DNA sequences encoding TRAIL are disclosed, along with expression vectors and transformed host cells useful in producing TRAIL polypeptides. Antibodies that specifically bind TRAIL are provided as well.
    Type: Grant
    Filed: June 25, 1996
    Date of Patent: June 9, 1998
    Assignee: Immunex Corporation
    Inventors: Steven R. Wiley, Raymond G. Goodwin